Virtu Financial LLC Sells 9,270 Shares of GSK plc (NYSE:GSK)

Virtu Financial LLC lessened its stake in GSK plc (NYSE:GSK - Free Report) by 31.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,272 shares of the pharmaceutical company's stock after selling 9,270 shares during the quarter. Virtu Financial LLC's holdings in GSK were worth $686,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in GSK. United Bank boosted its stake in shares of GSK by 7.3% in the 3rd quarter. United Bank now owns 25,785 shares of the pharmaceutical company's stock valued at $1,054,000 after purchasing an additional 1,760 shares in the last quarter. Thrivent Financial for Lutherans raised its position in GSK by 3.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 53,348 shares of the pharmaceutical company's stock worth $2,181,000 after purchasing an additional 1,737 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in GSK by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company's stock worth $4,971,000 after buying an additional 14,687 shares during the period. Cerity Partners LLC grew its position in shares of GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company's stock valued at $17,728,000 after buying an additional 165,556 shares during the last quarter. Finally, Larson Financial Group LLC grew its position in shares of GSK by 527.4% in the 3rd quarter. Larson Financial Group LLC now owns 1,807 shares of the pharmaceutical company's stock valued at $74,000 after buying an additional 1,519 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

Remove Ads

GSK Stock Up 0.2 %

Shares of GSK stock traded up $0.08 on Tuesday, hitting $38.65. The company had a trading volume of 5,835,438 shares, compared to its average volume of 4,348,173. The stock has a market capitalization of $80.00 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 1.12 and a beta of 0.58. The stock has a 50 day moving average of $36.77 and a 200-day moving average of $36.84. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.07%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK's payout ratio is presently 98.74%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GSK. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.